G6PD and malaria: Several randomized and controlled clinical trials on the safety and efficacy of ACT versus SLD-PQ have been conducted in South Africa[17], Tanzania[18, 19], Senegal[20], Switzerland[21], Burkina Faso[22], and Uganda[23], supporting the use of the WHO-recommended SLD-PQ without G6PD testing during the preelimination and elimination phases of malaria.